{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:07:54Z","timestamp":1786727274839,"version":"build-2736575974"},"reference-count":106,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K08HL168315"],"award-info":[{"award-number":["1K08HL168315"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI R01HL135121"],"award-info":[{"award-number":["NHLBI R01HL135121"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI R01HL132067"],"award-info":[{"award-number":["NHLBI R01HL132067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI R01HL166513"],"award-info":[{"award-number":["NHLBI R01HL166513"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advanced heart failure (HF) is characterized by changes in the structure, function, and metabolism of cardiac muscle. As the disease progresses, cardiomyocytes shift their ATP production from fatty acid oxidation to glycolysis. This shift results in an accumulation of lipid metabolites, particularly sphingolipids, which can disrupt normal cellular function and contribute to cardiac dysfunction. In animal models of obesity, accumulation of toxic sphingolipid metabolites in the heart has been described as cardiac lipotoxicity. In humans, HF is classified into two groups based on ejection fraction (EF): HF with reduced EF of less than 40% (HFrEF) and HF with preserved EF of greater than 50% (HFpEF). Despite shared risk factors and comorbidities, the structural and cellular differences between HFrEF and HFpEF distinguish them as separate conditions. Ceramides (Cer), a type of sphingolipid, have gained significant attention for their involvement in the development and prognosis of atherosclerotic disease and myocardial infarction, while sphingosine-1-phosphate, a downstream product of Cer, has shown cardioprotective properties. The aim of this review is to describe the role of sphingolipids in HF with reduced and preserved EF. By understanding the role of sphingolipids through animal and human studies, this review aims to pave the way for developing strategies that target abnormal signalling pathways in the failing heart, ultimately bridging the gap between scientific research and clinical applications.<\/jats:p>","DOI":"10.1093\/ehjopen\/oeaf035","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:14:06Z","timestamp":1746170046000},"source":"Crossref","is-referenced-by-count":5,"title":["The role of sphingolipids in heart failure"],"prefix":"10.1093","volume":"5","author":[{"given":"Rana","family":"Hamouche","sequence":"first","affiliation":[{"name":"Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A","family":"Summers","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism Research Center, Department of Nutrition and Integrative Physiology, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L","family":"Holland","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism Research Center, Department of Nutrition and Integrative Physiology, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutip","family":"Navankasattusas","sequence":"additional","affiliation":[{"name":"Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros G","family":"Drakos","sequence":"additional","affiliation":[{"name":"Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health & School of Medicine , Salt Lake City, UT 84132 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9350-2282","authenticated-orcid":false,"given":"Eleni","family":"Tseliou","sequence":"additional","affiliation":[{"name":"Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah , Salt Lake City, UT 84112 ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health & School of Medicine , Salt Lake City, UT 84132 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025062619185540400_oeaf035-B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"2025062619185540400_oeaf035-B2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1161\/CIRCRESAHA.113.302095","article-title":"Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes","volume":"113","author":"Kolwicz","year":"2013","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2025062619185540400_oeaf035-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","article-title":"Mitochondrial dysfunction and oxidative stress in heart disease","volume":"51","author":"Peoples","year":"2019","journal-title":"Exp Mol Med"},{"key":"2025062619185540400_oeaf035-B5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s44161-022-00028-6","article-title":"Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure","volume":"1","author":"Koenig","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2025062619185540400_oeaf035-B6","doi-asserted-by":"crossref","first-page":"e005708","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","article-title":"Plasma ceramides and sphingomyelins in relation to heart failure risk","volume":"12","author":"Lemaitre","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2025062619185540400_oeaf035-B7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI131838","article-title":"Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease","volume":"130","author":"Poss","year":"2020","journal-title":"J Clin Invest"},{"key":"2025062619185540400_oeaf035-B8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1161\/ATVBAHA.120.315530","article-title":"Ceramide scores predict cardiovascular risk in the community","volume":"41","author":"Vasile","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025062619185540400_oeaf035-B9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2025062619185540400_oeaf035-B10","first-page":"102","article-title":"Lysosomal storage disease: revealing lysosomal function and physiology","volume":"25","author":"Parkinson-Lawrence","year":"2010","journal-title":"Physiology (Bethesda)"},{"key":"2025062619185540400_oeaf035-B11","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1074\/jbc.M212307200","article-title":"A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids","volume":"278","author":"Chavez","year":"2003","journal-title":"J Biol Chem"},{"key":"2025062619185540400_oeaf035-B12","doi-asserted-by":"crossref","first-page":"12583","DOI":"10.1074\/jbc.M611157200","article-title":"Key role for ceramides in mediating insulin resistance in human muscle cells","volume":"282","author":"Pickersgill","year":"2007","journal-title":"J Biol Chem"},{"key":"2025062619185540400_oeaf035-B13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MOL.0b013e3283373b66","article-title":"Sphingolipids and insulin resistance: the five Ws","volume":"21","author":"Summers","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"2025062619185540400_oeaf035-B14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1471-4159.2002.00997.x","article-title":"Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis","volume":"82","author":"Han","year":"2002","journal-title":"J Neurochem"},{"key":"2025062619185540400_oeaf035-B15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","article-title":"Deregulation of sphingolipid metabolism in Alzheimer's disease","volume":"31","author":"He","year":"2010","journal-title":"Neurobiol Aging"},{"key":"2025062619185540400_oeaf035-B16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s12031-011-9687-z","article-title":"PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K\/AKT pathway","volume":"47","author":"S\u00e1nchez-Mora","year":"2012","journal-title":"J Mol Neurosci"},{"key":"2025062619185540400_oeaf035-B17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2018.01.012","article-title":"Alpha galactosidase A activity in Parkinson's disease","volume":"112","author":"Alcalay","year":"2018","journal-title":"Neurobiol Dis"},{"key":"2025062619185540400_oeaf035-B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"2025062619185540400_oeaf035-B19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metab"},{"key":"2025062619185540400_oeaf035-B20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157340308783565429","article-title":"Protein-mediated fatty acid uptake in the heart","volume":"4","author":"Chabowski","year":"2008","journal-title":"Curr Cardiol Rev"},{"key":"2025062619185540400_oeaf035-B21","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1093\/eurheartj\/ehab412","article-title":"Glucosylceramide synthase deficiency in the heart compromises \u03b21-adrenergic receptor trafficking","volume":"42","author":"Andersson","year":"2021","journal-title":"Eur Heart J"},{"key":"2025062619185540400_oeaf035-B22","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1194\/jlr.M800635-JLR200","article-title":"Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity","volume":"50","author":"Hu","year":"2009","journal-title":"J Lipid Res"},{"key":"2025062619185540400_oeaf035-B23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00109-023-02391-8","article-title":"Sphingolipids: drivers of cardiac fibrosis and atrial fibrillation","volume":"102","author":"Liu","year":"2024","journal-title":"J Mol Med (Berl)"},{"key":"2025062619185540400_oeaf035-B24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B25","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B26","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1093\/cvr\/cvac166","article-title":"Cardiac metabolism in HFpEF: from fuel to signalling","volume":"118","author":"Capone","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025062619185540400_oeaf035-B27","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","article-title":"The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure","volume":"33","author":"Cluntun","year":"2021","journal-title":"Cell Metab"},{"key":"2025062619185540400_oeaf035-B29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","article-title":"Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support","volume":"67","author":"Ahmad","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025062619185540400_oeaf035-B30","doi-asserted-by":"crossref","first-page":"e000542","DOI":"10.1161\/JAHA.113.000542","article-title":"A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients","volume":"2","author":"Kalim","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2025062619185540400_oeaf035-B31","first-page":"55","article-title":"An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure","volume":"42","author":"Taylor","year":"2001","journal-title":"J Nucl Med"},{"key":"2025062619185540400_oeaf035-B32","doi-asserted-by":"crossref","first-page":"e004953","DOI":"10.1161\/CIRCHEARTFAILURE.118.004953","article-title":"Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling","volume":"11","author":"Voros","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2025062619185540400_oeaf035-B33","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.106.645184","article-title":"Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure","volume":"114","author":"Tuunanen","year":"2006","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B34","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1161\/CIRCRESAHA.122.320334","article-title":"Animal models of dysregulated cardiac metabolism","volume":"130","author":"Bugger","year":"2022","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B35","doi-asserted-by":"crossref","first-page":"18429","DOI":"10.1074\/jbc.M111.296947","article-title":"Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction","volume":"287","author":"Lee","year":"2012","journal-title":"J Biol Chem"},{"key":"2025062619185540400_oeaf035-B36","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1161\/ATVBAHA.122.318048","article-title":"Ceramide metabolism in cardiovascular disease: a network with high therapeutic potential","volume":"42","author":"Zietzer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025062619185540400_oeaf035-B37","doi-asserted-by":"crossref","first-page":"25843","DOI":"10.1074\/jbc.R200009200","article-title":"De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway","volume":"277","author":"M","year":"2002","journal-title":"J Biol Chem"},{"key":"2025062619185540400_oeaf035-B38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/iub.319","article-title":"Mammalian ceramide synthases","volume":"62","author":"Levy","year":"2010","journal-title":"IUBMB Life"},{"key":"2025062619185540400_oeaf035-B39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1194\/jlr.M009142","article-title":"Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism","volume":"52","author":"Mullen","year":"2011","journal-title":"J Lipid Res"},{"key":"2025062619185540400_oeaf035-B40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-5793(97)01187-3","article-title":"Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum","volume":"416","author":"Michel","year":"1997","journal-title":"FEBS Lett"},{"key":"2025062619185540400_oeaf035-B41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.plipres.2012.12.001","article-title":"Molecular properties of various structurally defined sphingomyelins\u2014correlation of structure with function","volume":"52","author":"Peter Slotte","year":"2013","journal-title":"Prog Lipid Res"},{"key":"2025062619185540400_oeaf035-B42","doi-asserted-by":"crossref","first-page":"33110","DOI":"10.1074\/jbc.271.51.33110","article-title":"Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease","volume":"271","author":"Koch","year":"1996","journal-title":"J Biol Chem"},{"key":"2025062619185540400_oeaf035-B43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cellsig.2008.08.008","article-title":"Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease","volume":"21","author":"Pyne","year":"2009","journal-title":"Cell Signal"},{"key":"2025062619185540400_oeaf035-B44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nature02188","article-title":"Molecular machinery for non-vesicular trafficking of ceramide","volume":"426","author":"Hanada","year":"2003","journal-title":"Nature"},{"key":"2025062619185540400_oeaf035-B45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0962-8924(98)01249-5","article-title":"Glucosylceramide synthase and glycosphingolipid synthesis","volume":"8","author":"Ichikawa","year":"1998","journal-title":"Trends Cell Biol"},{"key":"2025062619185540400_oeaf035-B46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cellsig.2007.12.006","article-title":"The sphingolipid salvage pathway in ceramide metabolism and signaling","volume":"20","author":"Kitatani","year":"2008","journal-title":"Cell Signal"},{"key":"2025062619185540400_oeaf035-B47","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection methodology","volume":"51","author":"Hammad","year":"2010","journal-title":"J Lipid Res"},{"key":"2025062619185540400_oeaf035-B48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2017.07.143","article-title":"Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer","volume":"147","author":"Knapp","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025062619185540400_oeaf035-B49","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-12-1424","article-title":"Plasma sphingolipids and lung cancer: a population-based, nested case-control study","volume":"22","author":"Alberg","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025062619185540400_oeaf035-B50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cmet.2024.03.002","article-title":"Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity","volume":"36","author":"Petersen","year":"2024","journal-title":"Cell Metab"},{"key":"2025062619185540400_oeaf035-B51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jacbts.2017.12.005","article-title":"Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction","volume":"3","author":"de Carvalho","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2025062619185540400_oeaf035-B52","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"2025062619185540400_oeaf035-B53","doi-asserted-by":"crossref","first-page":"e007931","DOI":"10.1161\/JAHA.117.007931","article-title":"Ceramide remodeling and risk of cardiovascular events and mortality","volume":"7","author":"Peterson","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025062619185540400_oeaf035-B54","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1002\/ehf2.12885","article-title":"Relation between plasma ceramides and cardiovascular death in chronic heart failure: a subset analysis of the GISSI-HF trial","volume":"7","author":"Targher","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025062619185540400_oeaf035-B55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cjca.2014.12.007","article-title":"Ceramide is upregulated and associated with mortality in patients with chronic heart failure","volume":"31","author":"Yu","year":"2015","journal-title":"Can J Cardiol"},{"key":"2025062619185540400_oeaf035-B56","doi-asserted-by":"crossref","first-page":"e96203","DOI":"10.1172\/jci.insight.96203","article-title":"Increased de novo ceramide synthesis and accumulation in failing myocardium","volume":"2","author":"Ji","year":"2017","journal-title":"JCI Insight"},{"key":"2025062619185540400_oeaf035-B57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fphar.2017.00312","article-title":"Characterization and expression of sphingosine 1-phosphate receptors in human and rat heart","volume":"8","author":"Ahmed","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025062619185540400_oeaf035-B58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yjmcc.2017.07.004","article-title":"Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease","volume":"110","author":"Polzin","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"2025062619185540400_oeaf035-B59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12944-020-01262-2","article-title":"U-shaped association between plasma sphingosine-1-phosphate levels and mortality in patients with chronic systolic heart failure: a prospective cohort study","volume":"19","author":"Xue","year":"2020","journal-title":"Lipids Health Dis"},{"key":"2025062619185540400_oeaf035-B60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur Heart J"},{"key":"2025062619185540400_oeaf035-B61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12872-023-03623-y","article-title":"Circulating sphingolipids and relationship to cardiac remodelling before and following a low-energy diet in asymptomatic type 2 diabetes","volume":"24","author":"Brady","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2025062619185540400_oeaf035-B62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacbts.2023.11.006","article-title":"Cardiac substrate utilization and relationship to invasive exercise hemodynamic parameters in HFpEF","volume":"9","author":"O'Sullivan","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"2025062619185540400_oeaf035-B63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/oby.22038","article-title":"Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction","volume":"26","author":"Mikhalkova","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2025062619185540400_oeaf035-B64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/biomedicines10010135","article-title":"Implication of sphingolipid metabolism gene dysregulation and cardiac sphingosine-1-phosphate accumulation in heart failure","volume":"10","author":"P\u00e9rez-Carrillo","year":"2022","journal-title":"Biomedicines"},{"key":"2025062619185540400_oeaf035-B65","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1172\/JCI16751","article-title":"Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy","volume":"111","author":"Yagyu","year":"2003","journal-title":"J Clin Invest"},{"key":"2025062619185540400_oeaf035-B67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/01.RES.0000154079.20681.B9","article-title":"Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy","volume":"96","author":"Chiu","year":"2005","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1172\/JCI10947","article-title":"A novel mouse model of lipotoxic cardiomyopathy","volume":"107","author":"Chiu","year":"2001","journal-title":"J Clin Invest"},{"key":"2025062619185540400_oeaf035-B69","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ajpath.2020.04.006","article-title":"Mouse models of heart failure with preserved or reduced ejection fraction","volume":"190","author":"Noll","year":"2020","journal-title":"Am J Pathol"},{"key":"2025062619185540400_oeaf035-B70","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCHEARTFAILURE.114.001151","article-title":"Metabolomic analysis of pressure-overloaded and infarcted mouse hearts","volume":"7","author":"Sansbury","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2025062619185540400_oeaf035-B71","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.119.039610","article-title":"Preservation of acyl coenzyme A attenuates pathological and metabolic cardiac remodeling through selective lipid trafficking","volume":"139","author":"Goldenberg","year":"2019","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B72","doi-asserted-by":"crossref","first-page":"1263913","DOI":"10.3389\/fmolb.2023.1263913","article-title":"Transcriptional changes during isoproterenol-induced cardiac fibrosis in mice","volume":"10","author":"Nanda","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2025062619185540400_oeaf035-B73","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1172\/JCI63888","article-title":"Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes","volume":"122","author":"Russo","year":"2012","journal-title":"J Clin Invest"},{"key":"2025062619185540400_oeaf035-B74","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1096\/fj.201700300R","article-title":"Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes","volume":"32","author":"Law","year":"2018","journal-title":"FASEB J"},{"key":"2025062619185540400_oeaf035-B75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/cvr\/cvq266","article-title":"Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation","volume":"89","author":"Zhang","year":"2011","journal-title":"Cardiovasc Res"},{"key":"2025062619185540400_oeaf035-B76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/en.2012-1835","article-title":"Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db\/db mice","volume":"154","author":"Demarco","year":"2013","journal-title":"Endocrinology"},{"key":"2025062619185540400_oeaf035-B77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molmet.2018.12.008","article-title":"The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach","volume":"21","author":"Raichur","year":"2019","journal-title":"Mol Metab"},{"key":"2025062619185540400_oeaf035-B78","doi-asserted-by":"crossref","first-page":"H1795","DOI":"10.1152\/ajpheart.01023.2011","article-title":"Differential effects of high-fat diet on myocardial lipid metabolism in failing and nonfailing hearts with angiotensin II-mediated cardiac remodeling in mice","volume":"302","author":"Pellieux","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025062619185540400_oeaf035-B79","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by \u03b2-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"2025062619185540400_oeaf035-B80","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMoa053063","article-title":"Left ventricular assist device and drug therapy for the reversal of heart failure","volume":"355","author":"Birks","year":"2006","journal-title":"N Engl J Med"},{"key":"2025062619185540400_oeaf035-B81","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2016.07.743","article-title":"Cardiac recovery during long-term left ventricular assist device support","volume":"68","author":"Wever-Pinzon","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025062619185540400_oeaf035-B82","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jacc.2017.02.018","article-title":"Left ventricular assist device as a bridge to recovery for patients with advanced heart failure","volume":"69","author":"Jakovljevic","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025062619185540400_oeaf035-B83","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1161\/CIRCULATIONAHA.106.633180","article-title":"Torre-Amione G; LVAD Working Group. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group","volume":"115","author":"Maybaum","year":"2007","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B84","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jacc.2016.07.756","article-title":"Impact of ischemic heart failure etiology on cardiac recovery during mechanical unloading","volume":"68","author":"Wever-Pinzon","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025062619185540400_oeaf035-B85","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/eurheartj\/ehq353","article-title":"Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices","volume":"32","author":"Dandel","year":"2011","journal-title":"Eur Heart J"},{"key":"2025062619185540400_oeaf035-B86","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/CIRCULATIONAHA.119.044452","article-title":"The role of nonglycolytic glucose metabolism in myocardial recovery upon mechanical unloading and circulatory support in chronic heart failure","volume":"142","author":"Badolia","year":"2020","journal-title":"Circulation"},{"key":"2025062619185540400_oeaf035-B87","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacbts.2016.06.009","article-title":"Evidence of glycolysis up-regulation and pyruvate mitochondrial oxidation mismatch during mechanical unloading of the failing human heart: implications for cardiac reloading and conditioning","volume":"1","author":"Diakos","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2025062619185540400_oeaf035-B88","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.healun.2022.07.007","article-title":"Biology of myocardial recovery in advanced heart failure with long-term mechanical support","volume":"41","author":"Tseliou","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2025062619185540400_oeaf035-B89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phrs.2008.06.005","article-title":"Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice","volume":"58","author":"Park","year":"2008","journal-title":"Pharmacol Res"},{"key":"2025062619185540400_oeaf035-B90","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J Lipid Res"},{"key":"2025062619185540400_oeaf035-B91","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.humpath.2011.09.020","article-title":"Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study","volume":"43","author":"Chimenti","year":"2012","journal-title":"Hum Pathol"},{"key":"2025062619185540400_oeaf035-B92","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","article-title":"Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization","volume":"47","author":"Pieroni","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2025062619185540400_oeaf035-B93","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/jhg.2016.52","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis","volume":"61","author":"Seo","year":"2016","journal-title":"J Hum Genet"},{"key":"2025062619185540400_oeaf035-B94","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/biom13020274","article-title":"Acid ceramidase deficiency: bridging gaps between clinical presentation, mouse models, and future therapeutic interventions","volume":"13","author":"Kleynerman","year":"2023","journal-title":"Biomolecules"},{"key":"2025062619185540400_oeaf035-B95","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jmg.32.9.740","article-title":"Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation","volume":"32","author":"Chab\u00e1s","year":"1995","journal-title":"J Med Genet"},{"key":"2025062619185540400_oeaf035-B96","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0002-9149(84)80115-0","article-title":"Calcification of the ascending aorta and aortic and mitral valves in Gaucher's disease","volume":"54","author":"Casta","year":"1984","journal-title":"Am J Cardiol"},{"key":"2025062619185540400_oeaf035-B97","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0022-3476(85)80472-8","article-title":"Cardiac involvement in diseases characterized by beta-galactosidase deficiency","volume":"106","author":"Rosenberg","year":"1985","journal-title":"J Pediatr"},{"key":"2025062619185540400_oeaf035-B98","doi-asserted-by":"crossref","first-page":"10912","DOI":"10.1038\/s41598-018-29279-9","article-title":"Arylsulphatase A pseudodeficiency (ARSA-PD), hypertension and chronic renal disease in Aboriginal Australians","volume":"8","author":"Tang","year":"2018","journal-title":"Sci Rep"},{"key":"2025062619185540400_oeaf035-B99","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/gim.2013.4","article-title":"Morbidity and mortality in type B Niemann-Pick disease","volume":"15","author":"McGovern","year":"2013","journal-title":"Genet Med"},{"key":"2025062619185540400_oeaf035-B100","first-page":"202","article-title":"S1.4 Cardiovascular involvement in Pompe disease","volume":"30","author":"Limongelli","year":"2011","journal-title":"Acta Myol"},{"key":"2025062619185540400_oeaf035-B101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Pasquali SK; Late-Onset Treatment Study Investigators. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy","volume":"13","author":"Forsha","year":"2011","journal-title":"Genet Med"},{"key":"2025062619185540400_oeaf035-B102","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1440-1754.2002.00765.x","article-title":"Cardiac involvement in infantile Sandhoff disease","volume":"38","author":"Venugopalan","year":"2002","journal-title":"J Paediatr Child Health"},{"key":"2025062619185540400_oeaf035-B103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.braindev.2016.09.006","article-title":"Early cardiac involvement in an infantile Sandhoff disease case with novel mutations","volume":"39","author":"Lee","year":"2017","journal-title":"Brain Dev"},{"key":"2025062619185540400_oeaf035-B104","first-page":"15","article-title":"Review: metabolic cardiomyopathy and conduction system defects in children","volume":"34","author":"Gilbert-Barness","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"2025062619185540400_oeaf035-B105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbrc.2018.06.054","article-title":"Sphingomyelin phosphodiesterase 1 (SMPD1) mediates the attenuation of myocardial infarction-induced cardiac fibrosis by astaxanthin","volume":"503","author":"Shi","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2025062619185540400_oeaf035-B106","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/emmm.201202301","article-title":"Systemic ceramide accumulation leads to severe and varied pathological consequences","volume":"5","author":"Alayoubi","year":"2013","journal-title":"EMBO Mol Med"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf035\/63040820\/oeaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf035\/63040820\/oeaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:19:18Z","timestamp":1750979958000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeaf035\/8123683"}},"subtitle":[],"editor":[{"given":"Stefan","family":"Koudstaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeaf035","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,30]]},"article-number":"oeaf035"}}